This early research collaboration is not expected to have a material financial impact on BIND Therapeutics. Additional terms of the collaboration have not been disclosed.About ACCURINS®ACCURINS® are proprietary polymeric nanoparticles that are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS® have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities. We are developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators:
- Innovative medicines: Designing new therapeutic approaches by combining novel targeting methods and new classes of therapeutic payloads.
- Enabling potent pathway inhibitors: Enabling greater inhibition of important cellular pathways where that level of inhibition has been unachievable due to off target toxicity.
- Differentiated profile with approved drugs: Improving upon safety and efficacy with previously approved chemotherapeutic agents.
About BIND TherapeuticsBIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND'S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. BIND is developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators: Innovative medicines; enabling potent pathway inhibitors; and differentiated efficacy with approved drugs. BIND's internal discovery efforts are focused on designing oligonucleotide and immune-oncology-based ACCURINS®.BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada), Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals), Synergy Pharmaceuticals, PeptiDream and Affilogic to develop ACCURINS® based on their proprietary therapeutic payloads and/or targeting ligands. BIND's collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. BIND's collaboration with Pfizer has resulted in the selection of an Accurin candidate that is entering IND-enabling studies. For more information, please visit BIND's web site at www.bindtherapeutics.com. About AffilogicAffilogic is a privately-owned biotech company specialized in discovery and development of a novel class of targeting ligands called Nanofitins®, potent antibody-mimetics exhibiting high affinity and specificity for capture, targeting and interaction with biomolecules. Affilogic has designed Nanofitins® against 50+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation / translocation, and complex entities (Virus-like Particles, bacteria, whole cells). Nanofitin®-based drugs are currently being developed in collaboration with Ferring, Sanofi and other undisclosed pharmaceutical companies. Several early-stage programs are currently exploring
- Non-injectable administration of Nanofitins®
- Nanofitin®-Drug Conjugates
- Multifunctional Nanofitins®